This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Sambiah Thota in JAK Kinase Inhibition
Introduction
Sambiah Thota is an accomplished inventor based in Fremont, CA. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit JAK kinases. His work is crucial in addressing diseases associated with JAK2 activity.
Latest Patents
Sambiah Thota holds a patent for "Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases." This invention is directed to compounds of formula (I), where n, m, Y, R, R, R, and R are disclosed as isolated stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof. The patent also covers pharmaceutical compositions comprising these compounds and methods for using them in treating diseases linked to JAK2 activity. He has 1 patent to his name.
Career Highlights
Sambiah Thota is currently employed at Rigel Pharmaceuticals, Incorporated, where he continues to innovate in the pharmaceutical sector. His expertise in medicinal chemistry and drug development has positioned him as a valuable asset to his team.
Collaborations
Sambiah has collaborated with notable colleagues, including Somasekhar Bhamidipati and Jeffrey Clough. Their combined efforts contribute to advancing research and development in their field.
Conclusion
Sambiah Thota's work in developing JAK kinase inhibitors showcases his dedication to improving therapeutic options for patients. His innovative contributions are paving the way for future advancements in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile